Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
about
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsNetwork-based biomarkers in Alzheimer's disease: review and future directionsThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volumeBlood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.Novel plasma biomarker surrogating cerebral amyloid deposition.Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.Measurement of creatinine in human plasma using a functional porous polymer structure sensing motif.Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome.A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces.Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures.Reference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive ImpairmentValidation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.CSF Apo-E levels associate with cognitive decline and MRI changesBiomarkers in Sporadic and Familial Alzheimer's Disease.Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives.Physical activity predicts reduced plasma β amyloid in the Cardiovascular Health Study.Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.A plasma proteolysis pathway comprising blood coagulation proteasesRegional Hippocampal Atrophy and Higher Levels of Plasma Amyloid-Beta Are Associated With Subjective Memory Complaints in Nondemented Elderly Subjects.Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals.Secretases-related miRNAs in Alzheimer's disease: new approach for biomarker discovery.Antibody-Mimetic Peptoid Nanosheet for Label-Free Serum-Based Diagnosis of Alzheimer's Disease.Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease.Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.Recent Advances: Decoding Alzheimer's Disease With Stem Cells.Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.Asymmetry of Hippocampus and Amygdala Defect in Subjective Cognitive Decline Among the Community Dwelling Chinese.Aging and are determinative factors of plasma A42 levelsSubgroup identification in clinical trials via the predicted individual treatment effectTargeted Neurotransmitters Profiling Identifies Metabolic Signatures in Rat Brain by LC-MS/MS: Application in Insomnia, Depression and Alzheimer's Disease
P2860
Q26770708-5390B38F-85CA-42ED-BB61-54DE079F40C7Q26784569-2C00AFD5-1C2F-4211-B98E-4A4AA761F6DAQ27023864-6A9CE3ED-5512-48A2-A3BE-3D35824BF716Q30668465-54C3A36B-16B8-4114-B748-E0CE59813E36Q34630564-D4E6E821-7503-451C-BD21-66704E7CA452Q35060510-6B6F9059-F18C-47ED-8776-1BC1D1D38EFBQ35074431-2806C729-6DF7-4376-8551-4B733B5E43E4Q35185694-3F60B276-5AC5-4930-A72E-754FEFD416C8Q36010376-14F8DC16-05A3-4DD0-B9CF-89DCD78B317FQ36037548-B93FABF2-BB81-4B83-9542-AB4E99080155Q36327854-90C9BF67-6618-4260-AAEE-B7DE822805E1Q36827322-E17BC56E-EB2D-433A-930C-5ACFCD9BC601Q37231536-25A34B0C-93A0-4F17-A573-06C27C1EE237Q37300264-B09C1338-6243-46F6-BD6E-86E9BB4B2766Q37451440-9CC127C2-BFC7-494D-A195-8E2E12735EA5Q37600861-02C94EA8-9E7E-4061-8179-E8BD49940C9FQ37705204-D12906B0-0BEF-4CB9-A98A-1D6109E3B4D8Q38592041-50F4FAA9-11EE-4D17-A558-B781BE7543F2Q38680904-DE6F3F43-27CE-4D4B-B291-3E758A9EF186Q38690145-9A761958-AD27-4512-8D5B-E113D3084355Q38793329-83AFF938-A544-4678-B3CB-5136D017AAF9Q39451611-79EE3900-6536-4C1E-9E69-F3DE699B2EE8Q39539762-937C2EF9-FC80-4C95-875A-86A5AB933E7DQ40870087-C795B8B5-E4D8-4437-AA8F-F1E31888FFB1Q41097447-B3025338-828E-40D5-AE7C-78B40BC036A9Q41140682-78D0E5D0-1C1B-4106-B57C-C71B92E47970Q41690745-095489F5-2D99-494E-BB7B-E0ABEAD5C79BQ47974946-B4E2B059-CBC9-473D-A432-33542F5C5723Q48026851-416C2F6C-D0EB-45F9-B300-9A459FD0FD88Q50753131-6CA1AF10-6480-4744-8FBC-9DE9ECC0F6EEQ52148328-CA3EF741-E7CF-4EEB-A504-C8B8F9D66E27Q52603658-24C2C0E0-928D-47AC-901F-E3DDDF3ED7F3Q53462923-02D98A01-0D04-490A-BBC0-99F427BED7F2Q55260606-F6288E0C-3001-4E17-8BB9-ECB7C54FCF33Q57822409-52E9B137-FEA4-4924-B37C-9A42B61B422DQ58601718-DA484CC8-4CD5-4F00-8D32-D8E9F53F54B0Q58691246-650B1DED-EFEA-4E71-8592-D1BDFD40AEA9
P2860
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
@en
type
label
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
@en
prefLabel
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
@en
P2860
P356
P1476
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
@en
P2093
Jon B Toledo
Leslie M Shaw
P2860
P2888
P356
10.1186/ALZRT162
P407
P577
2013-03-08T00:00:00Z
P5875
P6179
1013420366